Literature DB >> 9070179

Complement component C5 deficiency reduces edema formation in murine ligation-induced acute pancreatitis.

L T Merriam1, C Webster, R J Joehl.   

Abstract

The complement cascade is activated in humans and animals with acute pancreatitis. Activation of complement component C5 liberates C5a, C5a-desarg, and terminal complement complexes (TCCs) that increase capillary permeability, edema, and leukocyte chemotaxis at injured sites. Complement activation plays a major role in pathogenesis of capillary leak and edema formation in severe acute pancreatitis; however, the contribution of C5 (C5a/C5a-desarg, TCCs) has not been defined. Using He gene mutant mice lacking circulating C5, the role of C5 in ligation-induced acute pancreatitis was evaluated. We performed the following experiments: C5-sufficient (Hc1/Hc1) and C5-deficient (Hc0/Hc0) mice had bile and pancreatic ducts ligated. Sham-operated mice had ducts dissected but not ligated. Mice were killed at 4, 8, and 24 hr after bilepancreatic duct ligation. Serologic and morphologic evidences of acute pancreatitis were evaluated. Pancreatic edema was assessed using analysis of pancreatic water content, histologic edema score, and determination of wet weight ratio. After 4, 8, and 24 hr of bile-pancreatic duct ligation, hyperamylasemia and histologic changes of acute pancreatitis were observed in both C5-deficient and C5-sufficient mice. Edema developed in all mice with acute pancreatitis. However, when compared to C5-sufficient mice, mice deficient in C5 developed significantly less pancreatic edema at both 8 and 24 hr of bile-pancreatic duct ligation. This difference was not observed 4 hr after induction of acute pancreatitis. We conclude that C5 contributes to edema formation in murine ligation-induced acute pancreatitis. The presence of an early C5-independent phase, in conjunction with the observation of significant edema in mice deficient in C5, suggests there are other mediators of edema formation in this acute pancreatitis model.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9070179     DOI: 10.1006/jsre.1996.4916

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Proteomic analysis (GeLC-MS/MS) of ePFT-collected pancreatic fluid in chronic pancreatitis.

Authors:  Joao A Paulo; Vivek Kadiyala; Linda S Lee; Peter A Banks; Darwin L Conwell; Hanno Steen
Journal:  J Proteome Res       Date:  2012-02-07       Impact factor: 4.466

2.  Review of experimental animal models of acute pancreatitis.

Authors:  Kim Hue Su; Christine Cuthbertson; Christopher Christophi
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

3.  Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo.

Authors:  J M Lubinski; L Wang; A M Soulika; R Burger; R A Wetsel; H Colten; G H Cohen; R J Eisenberg; J D Lambris; H M Friedman
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Complement Component 5 Mediates Development of Fibrosis, via Activation of Stellate Cells, in 2 Mouse Models of Chronic Pancreatitis.

Authors:  Matthias Sendler; Georg Beyer; Ujjwal M Mahajan; Vivien Kauschke; Sandrina Maertin; Claudia Schurmann; Georg Homuth; Uwe Völker; Henry Völzke; Walter Halangk; Thomas Wartmann; Frank-Ulrich Weiss; Peter Hegyi; Markus M Lerch; Julia Mayerle
Journal:  Gastroenterology       Date:  2015-05-19       Impact factor: 22.682

Review 5.  Complement in Pancreatic Disease-Perpetrator or Savior?

Authors:  Lucas Bettac; Stephanie Denk; Thomas Seufferlein; Markus Huber-Lang
Journal:  Front Immunol       Date:  2017-01-17       Impact factor: 7.561

6.  ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a.

Authors:  Kyung Hee Jung; Mi Kwon Son; Hong Hua Yan; Zhenghuan Fang; Juyoung Kim; Soo Jung Kim; Jung Hee Park; Ji Eun Lee; Young-Chan Yoon; Myeong Seong Seo; Beom Seok Han; Soyeon Ko; Young Ju Suh; Joo Han Lim; Don-Haeng Lee; Ziqiang Teo; Jonathan Wei Kiat Wee; Nguan Soon Tan; Soon-Sun Hong
Journal:  EMBO Mol Med       Date:  2020-07-07       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.